Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaip.2020.09.025 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The clinical question of mepolizumab in the long-term treatment of idiopathic chronic eosinophilic pneumonia; how long should we use mepolizumab?
Respir Med Case Rep
November 2024
Department of Respiratory Medicine, Kurashiki Central Hospital, Okayama, Japan.
The efficacy of mepolizumab as an alternative to glucocorticoids for treating idiopathic chronic eosinophilic pneumonia (ICEP) has been reported. However, various questions remain unanswered, such as the most appropriate dose and dosage interval of mepolizumab for ICEP, how long efficacy is maintained, how long administration should be continued, and whether and when discontinuation can be considered. We present herein three cases of refractory ICEP treated with mepolizumab at a dose of 100 mg every 4 or 8 weeks.
View Article and Find Full Text PDFThe Effects of Mepolizumab on CRSwNP: Real-Life Evidence.
J Pers Med
November 2024
Division of Internal Medicine and Clinical Immunology, Department of Translational Medical Sciences, University of Naples "Federico II", 80138 Naples, Italy.
: This study aims to evaluate the efficacy and safety of mepolizumab in the treatment of severe uncontrolled CRSwNP with or without comorbid asthma in a real-life setting over the first six months of therapy. : A total of 45 patients with nasal polyps with or without comorbid asthma were treated with mepolizumab (100 mg q4w) for 6 months. The following outcomes were assessed before therapy (V), and after 6 months (V): endoscopic nasal polyp score (NPS), nasal congestion score (NCS), sinonasal outcome test (SNOT-22), visual analog scale (VAS), nasal flow rate (PNIF), olfactory test (SS-I), and asthma control test (ACT).
View Article and Find Full Text PDFEarly Treatment Response to Mepolizumab Predicts Clinical Remission in Severe Eosinophilic Asthma.
J Allergy Clin Immunol Pract
November 2024
Center of Excellence in Treatable Traits, College of Health, Medicine and Wellbeing, University of Newcastle, New Lambton Heights, New South Wales, Australia; Asthma and Breathing Research Program, Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia.
Background: Mepolizumab can induce an early response and clinical remission in people with severe eosinophilic asthma (SEA).
Objective: To find whether early response to mepolizumab (100 mg) could predict future asthma remission and to identify the best predictor of treatment response to mepolizumab for achieving remission.
Methods: The Australian Mepolizumab Registry was used to investigate the early response to mepolizumab at 3 and 6 months and relate this to clinical remission at 12 months.
Long-term safety of mepolizumab for up to ∼10 years in patients with severe asthma: open-label extension study.
Ann Med
December 2024
Clinical Investigation, Allergy and Respiratory Research Unit, Fundacion CIDEA, Buenos Aires, Argentina.
Objectives: Long-term safety monitoring of mepolizumab is necessary to support real-world use for the treatment of severe asthma. This Long-Term Access Program assessed the safety and benefit:risk of mepolizumab in pediatric, adolescent, and adult patients with severe asthma.
Materials And Methods: This was a multicenter, Phase IIIb safety, open-label extension study of multiple prior studies assessing mepolizumab in addition to standard of care (Aug 2015 - Aug 2022).
Long-term efficacy of mepolizumab in patients with eosinophilic granulomatosis with polyangiitis: a propensity score matching analysis in the multicenter REVEAL cohort study.
Front Immunol
October 2024
Department of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Background: Mepolizumab (MPZ) has demonstrated efficacy in clinical trials for eosinophilic granulomatosis with polyangiitis (EGPA); however, few studies compare the disease course between patients treated with MPZ (MPZ group) and those who were not treated with MPZ (non-MPZ group) in real-world settings.
Objectives: This study aimed to compare the disease course and outcomes between the two groups and assess the long-term efficacy of MPZ in a multicenter cohort in Japan. Methods: We enrolled 113 EGPA patients registered in the cohort until June 2023.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!